Extended Data Fig. 1: Acquired clinical resistance to the mutant IDH2 inhibitor enasidenib (AG-221).
From: Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
a, b, Haematoxylin and eosin staining of bone marrow cells aspirated from patient A (a) and patient B (b) at indicated points in relation to treatment with AG-221. Remission images demonstrate decreased leukaemic blasts and increased myeloid differentiation that are reversed at the time of relapse. Images show 100× magnification. Images are representative fields of a single bone marrow aspiration performed at each time point.
